網頁

星期五, 9月 19, 2014

GOVERNOR PATRICK ANNOUNCES NANOBIOTIX’S EXPANSION INTO MASSACHUSETTS

GOVERNOR PATRICK ANNOUNCES NANOBIOTIX’S EXPANSION INTO MASSACHUSETTS
Nano-medicine Company to Open First U.S. Office in Boston
FRANCE – Friday, September 19, 2014 – Governor Deval Patrick today announced that Nanobiotix, a clinical-stage nano-medicine company pioneering novel approaches for the local treatment of cancer, will be opening its first U.S. office in Massachusetts. Governor Patrick met personally with officials from Nanobiotix at this year’s Bio Convention in San Diego this past June to explain the benefits of doing business in the Commonwealth. The announcement was made on the last day of the Governors Massachusetts-France Innovation Partnership Mission in Paris.

“Massachusetts leads the world in life sciences thanks to our growth strategy of investing in education, innovation and infrastructure,” said Governor Patrick. “We welcome Nanobiotix, and we look forward to working with them to create jobs and opportunities in the Commonwealth.”

Nanobiotix is focused on the development of NanoXray, a pipeline of products that are based on a physical mechanism of action. NanoXray products are built on the existing standard of care and can be used with existing radiation equipment available in almost every hospital worldwide.

"The Patrick Administration is committed to growing the Massachusetts economy through investments in education, innovation and infrastructure, so that we can build on our position as the global leader in life sciences," said Greg Bialecki, the Secretary of Housing and Economic Development. “I congratulate Nanobiotix on opening their first U.S. office in Massachusetts and look forward to working with them as they grow.”

To lead the development of the U.S. affiliate, Nanobiotix has appointed Patrick Tricoli as Vice President Corporate Development. Patrick has more than 25 years of experience within the pharmaceutical industry and joins Nanobiotix from SANOFI where he held a number of positions in both Corporate and Research Development.
“The opening of a U.S. affiliate is a key strategic step for Nanobiotix’s corporate development. This exciting move expands our international presence to the U.S.,” said Nanobiotix CEO, Laurent Lévy.“Massachusetts is the ideal location for us to access the breadth of professional talent, innovative research and clinical expertise in the nano-medicine field.”
“We are excited to welcome Nanobiotix to the Massachusetts Life Sciences community,” said Susan Windham-Bannister, Ph.D., President & CEO of the Massachusetts Life Sciences Center, the agency charged with implementing Governor Patrick’s 10-year, $1 billion Life Sciences Initiative. “This company's presence in Massachusetts will contribute to our economy, and strengthen both our life sciences ecosystem and the growing business ties between Massachusetts and France.  I am confident that Nanobiotix will find all of the resources and partners it needs to thrive in Massachusetts and thank them for choosing to grow in Massachusetts.”
About NANOBIOTIX
Nanobiotix is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers via multiple routes of administration.

Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma and locally advanced head and neck cancer. The company, based in Paris, France, has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.

Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP).

沒有留言: